Pharmasyntez as the largest domestic manufacturer of the socially significant pharmaceuticals of drugs for the treatment of socially significant diseases, such as tuberculosis, HIV, oncology, diabetes mellitus, hepatitis and orphan diseases, COVID-19, as well as hospital antibiotics, diabetes drugs, hormonal drugs and x-ray contrast agents in the company’s portfolio. The company’s product portfolio comprises over 250 items of the drugs in various dosage forms: capsules, tablets, granules, infusion solutions, dry sterile powders and lyophilizates, as well as solutions for injection. More than 80% of the drugs produced are included in the list of vital and essential drugs

Pharmasyntez was established in 1997. The production facilities are represented by five modern high-tech plants in the following cities: Ussuriysk, Irkutsk, Bratsk, Tyumen, and Saint Petersburg.

The annual production volume is more than 87 million packages. At the end of 2021, the revenue amounted to 790 mln USD.

Current ratings:

TOP-20 world leading pharmaceutical manufacturer in the Russian market:  

  • 4th by Total Value in hospital channel
  • 8th place in TOP-10 leading Pharmaceutical Companies in Russia according to Forbes 2021
  • 19th total sales in Russian pharmaceutical market

*Rating based on the data from DSM Group Analytical Company (Russian Pharmaceutical Market 2021)

One of the main strategic pillars for Pharmasyntez is to keep on providing constant access to innovative solutions for the treatment of the most vulnerable groups of patients, irrespective of any external circumstances whatsoever, based on respective United Nation’s general provisions.